The Quantellect read.As of Nov 19, 2026, 17 active firms cover Axsome Therapeutics Inc: 16 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $205.00 to $316.00, a moderate spread. The average target of $269.53 sits 101% above the current $134.19. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 15 to 16 over recent months. On the fundamentals, the Street sees revenue growth near 55% this year and 57% next, consensus EPS building from about $0.03 next quarter toward $3.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 active firms
Buy
Strong Buy00%
Buy1694%
Neutral16%
Sell00%
Strong Sell00%
Based on 17 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$269.53
+100.9% upside
Average target across 17 active firms as of Nov 19, 2026 vs $134.19 current
Highest Target$316.00
Average Target$269.53
Lowest Target$205.00
Detailed analyst forecasts for AXSM
Showing 1–17 of 17 named analysts shown · 17 active firms in the rating projection
As of Nov 19, 2026, 16 of 17 active firms rate AXSM a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AXSM EPS & revenue forecast
EPS · NEXT QUARTER
$0.03
Range $-0.21 – $0.27 · 2 analysts · -102% YoY
Next period, 2 analysts expect Axsome Therapeutics Inc to earn $0.03 a share (range $-0.21 – $0.27), versus $-1.26 a year earlier. Full-year consensus is $-2.53, growing to $3.38 the year after.
REVENUE · NEXT QUARTER
$297.5M
Range $277.2M – $335.5M · 2 analysts · +50% YoY
Revenue is expected to reach $297.5M (range $277.2M – $335.5M), +50.0% year-over-year. Full-year consensus is $952.2M, rising to $1.4B next year.
Top analysts covering Axsome Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AXSM.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$273.00+103.4% to target
Overall win rate
52%
+ Follow
#2
Joel Beatty
Baird · Rank #71
Buy
$246.00+83.3% to target
Overall win rate
50%
+ Follow
#3
Yatin Suneja
Guggenheim · Rank #84
Buy
$275.00+104.9% to target
Overall win rate
50%
+ Follow
#4
Ami Fadia
Needham · Rank #92
Buy
$268.00+99.7% to target
Overall win rate
46%
+ Follow
#5
David Amsellem
Piper Sandler · Rank #124
Buy
$235.00+75.1% to target
Overall win rate
50%
+ Follow
AXSM stock forecast FAQ
What is AXSM's average 12-month price target?+
The 17 active firms with a live target average $269.53 for Axsome Therapeutics Inc over the next 12 months, ranging from a $316.00 high to a $205.00 low, as of Nov 19, 2026.
Is AXSM stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 17 active firms as of Nov 19, 2026, 16 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AXSM?+
The Street-high target is $316.00 (Mizuho), and the Street-low is $205.00 (Leerink Partners). The average of all 17 active-firm targets is $269.53.
How many active Wall Street firms cover AXSM?+
17 active firms have a recognized rating on Axsome Therapeutics Inc as of Nov 19, 2026, and 17 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AXSM?+
Among analysts who currently cover AXSM, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $273.00 target.
What is Axsome Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.03 per share (range $-0.21 – $0.27) across 2 analysts. Full-year EPS is projected at $-2.53, rising to $3.38 the following year.
How much revenue is Axsome Therapeutics Inc expected to report next quarter?+
Consensus revenue is $297.5M (range $277.2M – $335.5M). Full-year revenue is projected at $952.2M, growing to $1.4B next year.
Have analysts been upgrading or downgrading AXSM lately?+
As of Nov 19, 2026, 16 of 17 active firms rate AXSM a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AXSM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.